Compare · ADVM vs BIIB
ADVM vs BIIB
Side-by-side comparison of Adverum Biotechnologies Inc. (ADVM) and Biogen Inc. (BIIB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ADVM and BIIB operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB carries a market cap of $37.46B.
- BIIB has hit the wire 10 times in the past 4 weeks while ADVM has been quiet.
- BIIB has more recent analyst coverage (25 ratings vs 7 for ADVM).
- Company
- Adverum Biotechnologies Inc.
- Biogen Inc.
- Price
- -
- -
- Market cap
- -
- $37.46B
- 1M return
- -
- +7.72%
- 1Y return
- -
- +53.86%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 0
- 10
- Recent ratings
- 7
- 25
Adverum Biotechnologies Inc.
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Latest ADVM
- SEC Form 15-12G filed by Adverum Biotechnologies Inc.
- SEC Form EFFECT filed by Adverum Biotechnologies Inc.
- SEC Form EFFECT filed by Adverum Biotechnologies Inc.
- SEC Form EFFECT filed by Adverum Biotechnologies Inc.
- CEO, PRESIDENT AND DIRECTOR Fischer Laurent exercised 150,000 shares at a strike of $4.20 and was granted 500,000 units of Common Stock - Performance Stock Units, closing all direct ownership in the company (SEC Form 4)
- CHIEF OPERATING OFFICER Soparkar Peter was granted 150,000 units of Common Stock - Performance Stock Units, closing all direct ownership in the company (SEC Form 4)
- Chief Medical Officer Ozden Rabia Gurses was granted 85,000 units of Common Stock - Performance Stock Units, closing all direct ownership in the company (SEC Form 4)
- CHIEF DEVELOPMENT OFFICER Seyedkazemi Setareh was granted 85,000 units of Common Stock - Performance Stock Units, closing all direct ownership in the company (SEC Form 4)
- CHIEF FINANCIAL OFFICER Rubinstein Linda M was granted 42,000 units of Common Stock - Performance Stock Units and exercised 48,750 shares at a strike of $4.20, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Hong Soo
Latest BIIB
- LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Now Available in Japan for Patients with Early Alzheimer’s Disease
- SEC Form SCHEDULE 13G filed by Biogen Inc.
- ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure
- Stoke Therapeutics to Present at Upcoming Investor Conferences in November
- Head of Research Grogan Jane converted options into 695 shares and covered exercise/tax liability with 345 shares, increasing direct ownership by 9% to 4,408 units (SEC Form 4)
- Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates
- Biogen upgraded by Argus with a new price target
- Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026
- SEC Form 10-Q filed by Biogen Inc.
- SEC Form 8-K filed by Biogen Inc.